Gland Pharma has announced the reappointment of Ms. Naina Lal Kidwai as an Independent Director. The decision, which was initially proposed in a postal ballot notice dated April 9, 2026, includes a remuneration package that may exceed 50% of the total remuneration payable to all Non-Executive Directors for the next five financial years, from FY 2026-27 to FY 2030-31.
The company has clarified that approval from its members through a special resolution will be obtained in each financial year where the remuneration payable to Ms. Kidwai exceeds the specified 50% threshold. This ensures adherence to corporate governance norms and provides transparency in remuneration practices.
The reappointment of Ms. Kidwai, who has a distinguished career in finance and corporate governance, is seen as a strategic move by Gland Pharma to strengthen its board with experienced and independent oversight.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).